2016 International Congress Archives - Page 149 of 207

Objective data in Parkinson’s disease therapy management – A retrospective analysis of the Parkinson’s kinetigraph (PKG) database

P. Lynch, Y. Zoellner, S. McGregor, M. Home (Minnetonka, MN, USA)
Objective decrement in Parkinson’s disease – A new parameter for the BRAIN tap test

H. Hasan, D.S. Athauda, T. Foltynie, G. Giovannoni, T. Warner, A.J. Lees, A. Noyce (East Riffa, Bahrain)
Objective measurement in clinical care of patients with Parkinson’s disease

M. Horne, K. Kotschet, M. Braybrook (Parkville, Australia)
Objective measures of Parkinsonian motor symptoms using a continuously worn smartwatch

N. Fixler, L. Reitblat, A. Wagner, S. Cohen, M. Afek, P. Bonato, J.F. Daneault, N. Golabchi, S. Moore, A. Patel, C. Cho, L. Bataille (Petach Tikva, Israel)
Objective methods for quantifying the deep brain stimulation (DBS) efficacy in subthalamic-nuclei (STN) neurons with microelectrode recording (MER) technology

V.R. Rama Raju, R.K. Mridula, R. Borgohain, V. Rama Raju (Hyderabad, India)
Objective movement recording in PD patient before and after STN-DBS

D. Flisar, B. Pikš, B. Meglic, Z. Pirtošek, G. Kramberger (Ljubljana, Slovenia)
Objective, unobtrusive assessment of bradykinesia in Parkinson’s disease

P.J.M. Bank, J. Marinus, J.H. de Groot, C.G.M. Meskers, J.J. van Hilten (Leiden, Netherlands)
Objectives of the MDS rare movement disorders study group

E.M. Gatto, A. Albanese, K. Bathia, F. Cardoso, M. Cesarini, A. Chade, P. Chana, A. De la Cerda:Chile, A. Espay, J. Etcheverry, J. Ferreira, P. Garcia Ruiz, J. Jankovic, H. Jinnah, R. Kaji, K. Kotschet, C. Marras, J. Miyasaki, F. Morgante, A. Münchau, P. Pal, M.C. Rodriguez Oroz, M. Rodríguez Violante, A. Sanguinetti, L. Schoel (Buenos Aires, Argentina)
Objectivisation of postural disorders in patients with Parkinson’s disease during the screening stage for DBS

A.G. Buniak, I.P. Maryenko, S.A. Likhachev (Minsk, Belarus)
Occurrence and pattern of cognitive deficits in prodromal Parkinson’s disease

C. Pausch, J. Spiegel, F.A. Wollenweber, C. Bayer, U. Dillmann, K. Fassbender, S. Behnke (Homburg Saar, Germany)
Ocular flutter in alcohol withdrawal syndrome

K.P. Frei, M. Dastjerdi, F.B. Pedouim, L.H. Sovory, K. Dashtipour (Loma Linda, CA, USA)
Oculopalatal myoclonus after stroke

B. Klysz, I. Sarzynska-Dlugosz, A. Czlonkowska, I. Kurkowska-Jastrzebska (Warsaw, Poland)
Olfaction analysis in spinocerebellar ataxia type 10 and type 3 comparing with healthy controls and PD

M. Moscovich, A. Moro, R. Munhoz, H.G. Teive, L.S. Moryiama (Curitiba, Brazil)
Olfaction and gray matter volume in Parkinson’s disease. A voxel-based morphometry study

K. Witt, N. Schmidt, O. Granert, L. Paschen, S. Wolff, G. Deuschl (Kiel, Germany)
Olfactory deficit characterization in Parkinson’s disease

A.M. Crespo-Cuevas, L. Ispierto, A. Planas, D. Vilas, A. Planas, J. Sanchez, I. Isern, J. De Haro, R. Alvarez (Badalona, Spain)
Olfactory loss – early non-motor symptom in Parkinson’s disease

A. Kadirova, K. Mirzaeva, G. Rakhimbaeva (Tashkent, Uzbekistan)
Olfactory performance and resting state functional connectivity in non-demented drug naïve patients with Parkinson’s disease

M. Sunwoo, J.H. Ham, J.Y. Hong, Y.H. Sohn, P.H. Lee (Seongnam, Korea)
Olfactory testing in differential diagnosis of atypical essential tremor and tremor-dominant Parkinson’s disease

O. Izhboldina, I. Zhukova, N. Zhukova, V. Alifirova, A. Latypova, M. Nikitina, Y. Mironova (Tomsk, Russia)
Oligomeric alpha-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease

A.K. Emelyanov, G.V. Baydakova, P.A. Andoskin, M.A. Nikolaev, K.A. Senkevich, I.V. Milyukhina, A.F. Yakimovskii, A.A. Timofeeva, E.Y. Fedotova, E.P. Nuzhnyi, S.N. Illarioshkin, E.Y. Zakharova, S.N. Pchelina (Saint-Petersburg, Russia)
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

N.K. Majbour, N.N. Vaikath, K.D. Dijk, M. Ardah, C.E. Teunissen, H.W. Berendse, W.D.J. Berg, O.M.A. El-Agnaf (Amsterdam, Netherlands)
Onset and stabilization of opicapone treatment effects in fluctuating Parkinson’s disease patients: Exploratory by-week efficacy analysis of pooled phase III studies

A. Lees, J. Ferreira, H. Reichmann, E. Tolosa, A. Santos, C. Oliveira, I. Oliveira, N. Lopes, J.F. Rocha, P. Soares-da-Silva (London, United Kingdom)
Onset-related subtypes of Parkinson’s disease differ in the patterns of striatal functional connectivity: A resting-state functional MRI study

Y. Hou, J. Yang, C. Luo, R. Ou, W. Song, Q. Gong, H. Shang (Chengdu, People's Republic of China)
Opicapone in fluctuating Parkinson’s disease patients: OFF- and ON-time responder post-hoc analyses of pooled phase III studies

A. Lees, J. Ferreira, T. Müller, F. Stocchi, C. Oliveira, A. Santos, N. Lopes, J.F. Rocha, P. Soares-da-Silva (London, United Kingdom)
Opioid K receptor variant delays the onset of dyskinesias in Parkinson’s disease

R. Cilia, R. Asselta, R. Benfante, E. Cereda, D. Vallauri, L. Marabini, D. Fornasari, S. Goldwurm, G. Pezzoli (Milan, Italy)
Opsoclonus myoclonus ataxia syndrome in a seronegative patient with disseminated cryptococcosis: The first case report

K. Sakdisornchai, J. Sringean, O. Jitkritsadakul, R. Bhidayasiri (Bangkok, Thailand)
Optic nerve integration as a visuospatial cognitive predictor in Parkinson’s disease

J.J. Lee, Y. Lee, S.J. Chung, Y.H. Sohn, P.H. Lee (Seoul, Korea)
Optimization of 6-hydroxydopamine animal model of early stage Parkinson´s disease for the assessment of neurorestorative therapies

J.V. Leikas, T.M. Kääriäinen, A.J. Jalkanen, M. Lehtonen, T. Rantamäki, M.M. Forsberg (Kuopio, Finland)
Optogenetic silencing of locus coeruleus activity in mice impairs cognitive flexibility in an attentional set-shifting task

K. Janitzky, M. Lippert, A. Engelhorn, J. Tegtmeier, J. Goldschmidt, H.J. Heinze, F.W. Ohl (Magdeburg, Germany)
Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study

A. Agro, B. Dzyngel, T. Bilbault, E.J. Pappert (Toronto, ON, Canada)
Orientation of attention affects onset of head saccades: A novel representation of the Posner cueing effect

I.M. Beiser, B. Quinlivan, E. McGovern, L.J. Williams, S. Narasimham, O. Killian, R. Beck, S. O'Riordan, J.S. Butler, R.B. Reilly, M. Hutchinson (Dublin, Ireland)
Orthostatic intolerance and falls in Parkinson’s disease

A. Fanciulli, C. Dallinger, G. Goebel, R. Granata, S. Duerr, F. Sprenger, F. Krismer, C. Mueller, S. Boesch, M. Nocker, C. Scherfler, K. Seppi, W. Poewe, G.K. Wenning (Innsbruck, Austria)
Orthostatic tremor: A literature review of clinical data

D.E. Bhatti, D. Torres-Russotto (Omaha, NE, USA)
Orthostatic tremor: Disease progression and disability

N. Vijiaratnam, D. Siresena, E. Paul, K.L. Bertram, D.R. Williams (Melbourne, Australia)
Orthostatic tremor: Is deep brain stimulation better than spinal cord stimulation?

H.L. Chiang, Y. Tai, V.S.C. Fung, N. Mahant (Sydney, Australia)
Ortostatic myoclonus: A report of four cases

Z.F. Aldaajani, F.C.F. Chang, N. Mahant, S.D. Kim, V.S.C. Fung (Sydney, Australia)
Osmotic demyelination syndrome with dystonia and parkinsonism responsive to dopaminergic therapy

L.E. Katus, S.J. Frucht (New York, NY, USA)
Osteopathic manipulative treatment in Parkinson’s disease: Preliminary results of a double blind sham-controlled cross-over study

S. Varanese, L. Cicchitti, G. Travaglini, V. Carafa, N. Modugno, S. Spinelli, F. Marsicano, M. Mistichelli, F. Marsicano, F. Giorgini, M. Verzella (Pozzilli, Italy)
Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms

B. Magennis, E.A. Donlon, E.M. Fallon, T. Lynch (Dublin, Ireland)
Overlapping corticobasal syndromes: The many faces of the Armstrong criteria

A. Pilotto, W. Maetzler, M. Synofzik, E. Schaeffer, C. Schulte, M.A. Hobert, K. Srulijes, T. Gasser, D. Berg (Tübingen, Germany)
Oxysterol and chitotriosidase as biomarkers for atypical Parkinsonian symptoms?

M. Schuberth, G. Nübling, J. Hauer, T. Marquardt, S. Lorenzl (München, Germany)